The Effect of Iron Chelators on urine Beta Microglobulin(β2M) and Serum Sodium on Patients with Thalassemia Major

Document Type : Original Article


1 Assistant Professor of Nephrology, Department of Internal Medicine, Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Medical Resident, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Assistant Professor of Hematology & Oncology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



Background and Objectives Thalassemia is the most common genetic disease associated with the body's recurrent blood transfusions and iron overload. Iron chelators can reduce the adverse effects of iron overload through various mechanisms. However, concerns have recently been raised about their negative impact on renal function. The current study, therefore, examined the effect of different iron chelators on renal function in patients with thalassemia major. Subjects and Methods This cross-sectional descriptive study included primary thalassemia patients (5 - 25 years) referring to Ahwaz Thalassemia Center for regular blood transfusion and regular treatment with iron chelators. They were divided into 3 groups (deferiprone 60-80 mg/kg/d, deferasirox 15-35 mg/kg/d and deferoxamine 11-48 mg/kg/d). Blood and 24-hour urine samples were collected to determine glomerular filtration rate (GFR) and biochemical factors. Results No significant difference was observed between the studied groups in terms of GFR, urine albumin, serum creatinine, serum cystatin C, serum and urine phosphorus, and urine sodium (p > 0.05), but serum sodium and urine β2microglobulin (β2M) were significantly different between the studied groups (p < 0.05). Serum sodium was significantly higher in the deferiprone group compared to the control (P=0.004). Urine β2M was significantly higher in the deferoxamine and deferasirox groups in comparison with the control group (P=0.041, P=0.013). Finally, serum sodium was significantly higher in the deferiprone and deferasirox groups than that in the deferoxamine group (P=0.001, P=0.021). Conclusion Urine beta-2 microglobulin increased in patients receiving deferoxamine and deferasirox compared to the control group, which might indicate primary kidney damage.


Asieh Aref [PumMed] [Google Scholar]

Sara Mosavi Larijani [PumMed] [Google Scholar]

Ali Ehsanpour [PumMed] [Google Scholar]

Shokouh Shayanpour [PumMed] [Google Scholar]


Main Subjects

[1] Muncie Jr HL, Campbell JS. Alpha and beta thalassemia. American family physician. 2009 Aug 15;80(4):339-44. [PMID]
[2] Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harbor perspectives in medicine. 2012 Dec;2(12). [10.1101/csh perspect.a011726 ] [PMID]
[3] Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. The Lancet. 2018 Jan 13;391(10116):155-67. [10.1016/S0140-6736(17)31822-6] [PMID]
[4] Chowdhury PK, Saha M, Basu A, Chowdhury D, kumar Jena R. Profile of Iron Overload in Nontransfusion Dependent Hb E Beta Thalassaemia Patients-Is It Different?. Blood. 2015 Dec 3;126(23):4557. [ Link]
[5] Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology Education Program Book. 2017 Dec 8;2017(1):265-71. [10.1182/asheducation-2017.1.265 ] [PMID]
[6] Saito H. Metabolism of iron stores. Nagoya journal of medical science. 2014 Aug;76(3-4):235. [PMID]
[7] Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica. 2010 Apr 1;123(3):148-52.
[10.1159/000287238 ] [PMID]
[8] Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clinical therapeutics. 2015 Dec 1;37(12):2866-77. [10.1016/j.clinthera.2015.10.001 ] [PMID]
[9] Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian journal of pediatrics. 2010 Dec;36:1-0. [10.1186/1824-7288-36-39 ] [PMID]
[10] Wei HY, Yang CP, Cheng CH, Lo FS. Fanconi syndrome in a patient with β‐thalassemia major after using deferasirox for 27 months. Transfusion. 2011 May;51(5):949-54. [10.1111/j. 1537-2995.2010.02939.x ] [PMID]
[11] Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatric blood & cancer. 2011 Apr;56(4):674-6. [10.1002/ pbc.22711 ] [PMID]
[12] Badeli H, Baghersalimi A, Eslami S, Saadat F, Rad AH, Basavand R, Papkiadeh SR, Darbandi B, Kooti W, Peluso I. Early kidney damage markers after deferasirox treatment in patients with thalassemia major: a case-control study. Oxidative Medicine and Cellular Longevity. 2019 Apr 21;2019. [10.1155/2019/ 5461617 ] [PMID]
[13] Zafari M, Aghamohammady A. Comparison of Beta-2 Microglobulin Level and Some Variables Between Thalassemia Major Patients Who Treated by Desferal and Control Group. Zahedan Journal of Research in Medical Sciences. 2017 Oct 31;19(10). [Link]
[14] Lapatsanis P, Sbyrakis S, Vretos C, Karaklis A, Doxiadis S. Phosphaturia in thalassemia. Pediatrics. 1976 Dec 1;58(6):885-92. [PMID]
[15] Aldudak B, Bayazit AK, Noyan A, Özel A, Anarat A, Sasmaz I,
Kilinç Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with β-thalassemia major. Pediatric nephrology. 2000 Oct;15:109-12. [10.1007/s004670000434] [PMID]
[16] VOLTI SL DGF, SCHILIRÒ G. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Children. 1990:144(10):1069-70. [Link]
[17] Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. American Journal of Diseases of Children. 1989 Sep 1;143(9):1077-80. [10.1001/ archpedi.1989.02150210113029 ] [PMID]
[18] Rigalleau V, Beauvieux MC, Lasseur C, Chauveau P, Raffaitin C, Perlemoine C, Barthe N, Combe C, Gin H. The combination of cystatin C and serum creatinine improves the monitoring of kidney function in patients with diabetes and chronic kidney disease. Clinical chemistry. 2007 Nov 1;53(11):1988-9. [10. 1373/clinchem.2007.092171 ] [PMID]